SCHEMBL3567802

SCHEMBL3567802

COC(=O)c1ccc2c3c(ccc2c1)N(C(=O)OC(C)(C)C)CC3CCl

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 2/20 0.43
HDAC6 Q9UBN7 2/20 0.43
LCK P06239 1/20 0.40
NPC1 O15118 3/20 0.35
MAPT P10636 3/20 0.35
KDM4E B2RXH2 2/20 0.35
RAB9A P51151 2/20 0.35
HPGD P15428 2/20 0.35
ALDH1A1 P00352 2/20 0.35
ADH1A P07327 1/20 0.35
KIT P10721 1/20 0.35
FLT1 P17948 1/20 0.35
FLT4 P35916 1/20 0.35
KDR P35968 1/20 0.35
ABL2 P42684 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
NR1H4 Q96RI1 4/20 0.34
UCHL1 P09936 1/20 0.34
USP30 Q70CQ3 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3567525 0.83 ADH1A (0.37) HDAC1HDAC6NPC1MAPTHPGD
SCHEMBL3569852 0.82 GPR119 (0.39) ADH1AKITFLT1FLT4KDR
SCHEMBL3564342 0.82 GPR119 (0.42) NR1H2
SCHEMBL12596942 0.82 ADH1A (0.44) HDAC1HDAC6MAPTKDM4EALDH1A1
SCHEMBL2398132 0.82 ADH1A (0.44) HDAC1HDAC6MAPTKDM4EALDH1A1
SCHEMBL20615472 0.79 HDAC1 (0.43) HDAC1HDAC6HPGDADH1AKIT
SCHEMBL3559992 0.79 ADH1A (0.37) LCKNPC1MAPTKDM4ERAB9A
SCHEMBL13344989 0.79 LCK (0.42) LCKNPC1MAPTKDM4ERAB9A
SCHEMBL3562025 0.77 GPR119 (0.39) ADH1AKITFLT1FLT4KDR
SCHEMBL3556352 0.77 GPR119 (0.42) NR1H2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7718688-B2 Nitrobenzindoles and their use in cancer therapy AUCKLAND UNISERVICES LIMITED (NZ) 2010-05-18 US disclosed
US-20080119442-A1 as hypoxia-selective drugs and radiosensitizers for cancer therapy; nitroreductase inhibitor; 1-(Chloromethyl)-5,6-dinitro-3-(5,6,7-trimethoxyindol-2-carbonyl)-1,2-dihydro-3H-benzo[e]indole; halogenation of naphthalene derivative followed by hydration and cyclization AUCKLAND UNISERVICES LIMITED (NZ) 2008-05-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119442-A1 as hypoxia-selective drugs and radiosensitizers for cancer therapy; nitroreductase inhibitor; 1-(Chloromethyl)-5,6-dinitro-3-(5,6,7-trimethoxyindol-2-carbonyl)-1,2-dihydro-3H-benzo[e]indole; halogenation of naphthalene derivative followed by hydration and cyclization HIF1AN, HYOU1, HIF1A HDAC1 440/4885HDAC6 1257/4885LCK 4427/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.